Showing 1 - 7 results of 7 for search 'Maria Lagerström-Fermer', query time: 0.03s Refine Results
  1. 1
    4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease.

    4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease. by Johan Jirholt, Bengt Asling, Paul Hammond, Geoffrey Davidson, Mikael Knutsson, Anna Walentinsson, Jörgen M Jensen, Anders Lehmann, Lars Agreus, Maria Lagerström-Fermer

    Published 2011-04-01
    Get full text
    Article
  2. 2
    Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial

    Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial by Vesa Anttila, Antti Saraste, Juhani Knuuti, Pekka Jaakkola, Marja Hedman, Sara Svedlund, Maria Lagerström-Fermér, Magnus Kjaer, Anders Jeppsson, Li-Ming Gan

    Published 2020-09-01
    Get full text
    Article
  3. 3
    Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

    Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction by Karin Nelander, Maria Lagerstrom‐Fermer, Carl Amilon, Erik Michaëlsson, Maria Heijer, Magnus Kjaer, Muir Russell, David Han, Eva‐Lotte Lindstedt, Carl Whatling, Li‐Ming Gan, Hans Ericsson

    Published 2021-05-01
    Get full text
    Article
  4. 4
    Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

    Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction by Eva Prescott, John Pernow, Antti Saraste, Axel Åkerblom, Oskar Angerås, David Erlinge, Erik L. Grove, Marja Hedman, Lisette O. Jensen, Sara Svedlund, Magnus Kjaer, Maria Lagerström-Fermér, Li-Ming Gan

    Published 2020-09-01
    Get full text
    Article
  5. 5
    Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction

    Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction by Mikael Erhardsson, Ulrika Ljung Faxén, Ashwin Venkateshvaran, Sara Svedlund, Antti Saraste, Maria Lagerström Fermer, Li‐Ming Gan, Sanjiv J. Shah, Jasper Tromp, Carolyn SP Lam, Lars H. Lund, Camilla Hage

    Published 2023-12-01
    Get full text
    Article
  6. 6
    Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

    Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes by Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson

    Published 2019-02-01
    Get full text
    Article
  7. 7
    Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study

    Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study by Ravi B. Patel, Carolyn S. P. Lam, Sara Svedlund, Antti Saraste, Camilla Hage, Ru-San Tan, Lauren Beussink-Nelson, Jasper Tromp, Cynthia Sanchez, Joyce Njoroge, Stanley A. Swat, Ulrika Ljung Faxén, Maria Lagerstrom Fermer, Ashwin Venkateshvaran, Li-Ming Gan, Lars H. Lund, Sanjiv J. Shah

    Published 2021-03-01
    Get full text
    Article

Search Tools: